logo

Protalix Biotherapeutics Inc. (PLX)



Trade PLX now with
  Date
  Headline
5/11/2020 6:54:12 AM Protalix Reports Positive Topline Results From Phase III BRIDGE Clinical Trial Of PRX-102
3/16/2020 6:53:36 AM Protalix Agrees To Conduct Feasibility Study With Kirin On Production Of Novel Complex Protein
3/12/2020 8:07:45 AM Protalix BioTherapeutics Q4 Net Profit $0.3 Mln Or $0.02 Per Share
3/12/2020 7:59:26 AM Protalix BioTherapeutics Announces $43.7 Mln In Financing To Further Advance Its Programs In Fabry Disease
2/6/2020 6:52:19 AM Protalix, Chiesi Farmaceutici Announce Receipt Of Agreement Letter For Initial Pediatric Study Plan For PRX-102
12/19/2019 6:51:50 AM Protalix BioTherapeutics Appoints Pol Boudes And Gwen Melincoff To Its Board
12/9/2019 4:07:05 PM Protalix BioTherapeutics Announces 1-for-10 Reverse Stock Split
11/27/2019 6:52:08 AM Protalix BioTherapeutics Hosts Key Opinion Leader Meeting On PRX-102 Drug Candidate
11/18/2019 6:58:05 AM Protalix BioTherapeutics And Chiesi Complete Successful Pre-BLA Meeting With FDA For Pegunigalsidase Alfa
11/7/2019 6:53:07 AM Protalix BioTherapeutics Q3 Loss/shr Narrows To $0.02 From $0.04 Prior Year
10/17/2019 7:48:58 AM Protalix Says Positive 12-Month Interim Data From BRIDGE Phase III Open Label Switch-over Study Of Pegunigalsidase Alfa
9/24/2019 7:04:41 AM Protalix BioTherapeutics And Chiesi Group Complete Enrollment In The Third Phase III Clinical Trial Of PRX-102
8/8/2019 6:15:54 AM Protalix BioTherapeutics H1 Net Loss $15.0 Mln Or $0.10/Shr Vs Loss Of $15.7 Mln Or $0.11/Shr Last Year